Antitumour and antiangiogenic effects of Aplidin® in the 5TMM syngeneic models of multiple myeloma

Por Caers, J, Menu, E, De Raeve, H, Lepage, D, Van Valckenborgh, E, Van Camp, B, Alvarez, E, Vanderkerken, K
Publicado em 2008

Murine 5T multiple myeloma cells induce angiogenesis in vitro and in vivo

Por Van Valckenborgh, E, De Raeve, H, Devy, L, Blacher, S, Munaut, C, Noël, A, Van Marck, E, Van Riet, I, Van Camp, B, Vanderkerken, K
Publicado em 2002

Tumor-initiating capacity of CD138− in and CD138+ tumour cells in the 5T33 multiple myeloma model

Por Van Valckenborgh, E, Matsui, W, Agarwal, P, Lub, S, Dehui, X, De Bruyne, E, Menu, E, Empsen, C, van Grunsven, L, Agarwal, J, Wang, Q, Jernberg-Wiklund, H, Vanderkerken, K
Publicado no Leukemia (2012)